The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment. Nusantara Medical Science Journal, v. 6, n. 2, p. 103–115, 20 Jan.2022.